Cardiovascular events with increased lipoprotein-associated phospholipase A 2 and low high-density lipoprotein-cholesterol the veterans affairs HDL intervention trial

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 6, 2008, Pages 1172-1178

  Robins, Sander J ^a,f   Collins, Dorothea ^b   Nelson, Jeanenne J ^c   Bloomfield, Hanna E ^d   Asztalos, Bela F ^e  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c GLAXOSMITHKLINE   (United States)

^d VA MEDICAL CENTER   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f FRAMINGHAM HEART STUDY   (United States)

Author keywords

Cardiovascular events; Gemfibrozil; High density lipoproteins; Inflammation; Lipoprotein associated phospholipase A 2

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SECONDARY PREVENTION; STROKE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; BLOOD; CARDIOVASCULAR DISEASE; FOLLOW UP; MIDDLE AGED; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; ANTILIPEMIC AGENTS; APOLIPOPROTEINS B; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FOLLOW-UP STUDIES; GEMFIBROZIL; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STROKE; TRIGLYCERIDES;

EID: 44649097081     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.160739     Document Type: Article

References (30)

1. 2 as an independent predictor of coronary heart disease. N Engl J Med, 2000;343:1148-1155.
2. 2 activity is associated with risk of coronary heart disease and ischemic stroke. The Rotterdam Study. Circulation, 2005;111:570-575.
3. 2 adds to risk prediction of incident coronary events by C-reactive protein in apparendy healthy middle-aged men from the general population. Results from the 14-year follow-up of a large cohort from southern Germany. Circulation, 2004; 110:1903-1.908.
4. 2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol. 2006;26:1586-1593.
5. 2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE 1T-TIMI 22 (Pravastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. emulation, 2006;113:1745-1752.
6. Stafforini DM, McIntyre TM, Carter ME, Prescott SM. Human plasma platelet-activating factor acetyIhydrolase. Association with lipoprotein particles and role in the degredation of platelet-activating factor. J Biol Chem. 1987;262:4215-4222.
7. 2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem. 2005;51: 22642273.
8. Stafforini DM, Carter ME, Zimmerman GA, Mclntyre TM, Prescott. SM. Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma. Proc Natl Acad Sci USA. 1.989;86: 2393-2397.
9. 2 and coronary artery disease: Focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis. 2005;182: 181-188.
10. 2: distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis. 2007;190:388-396.
11. Founder N, de la Llera Moya M!, Burkey BF, Swaney JB, Paterniti J, Moatti N, Atger V, Rothblat GH. Role of HDL phospholipid in efflux of cell cholesterol to whole serum: studies with human apoA-I transgenic rats. J Lipid Res. 1996:37:1704-1711.
12. Jian B, de la Llera Moya M, Royer L, Rothblat G, Francone O, Swaney JB. Modification of the cholesterol efflux properties of human serum by enrichment with phospholipid. J Lipid Res. 1997;38:734-744.
13. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 1995;15:1987-1994.
14. Cockerill GW, Huehns TY, Weerasinghe A, Stocker C, Lerch PG, Miller NE, Haskard DO. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation. 2001;103:108-112.
15. Baker PW, Rye K-A, Gamble JR, Vadas MA, Barter PJ. Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell molecule expression. J Lipid Res. 2000; 41:1261-1267.
16. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low HDL-cholesteroi. N Engl J Med. 1999;341:410-418.
17. Rubins HB, Robins SJ, Collins D. The Veterans Affairs High-Density Lipoprotein Intervention Trial: Baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Am J Cardiol. 1996;78:572-575.
18. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001; 285:1585-1591.
19. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-Density lipoprotein Intervention Trial (VA-HIT). Arch Intern Med. 2002;162:25972604.
20. Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, Nauck M, Bohm BO, Marz W. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors. The Ludwigshafen Risk and Cardiovascular Health Study. Circulation. 2005;111:980-987.
21. Tsimihodimos V, Karabina S-A P, Tambaki AP, Bairaktari E, Miltiadous G, Goudevenos JA, Cariolou MA, Chapman MJ, Tselepis AD, Elisaf M. Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res. 2002;43:256-263.
22. Surya II, Mommersteeg M, Erkelens DW, Akkerman JW. PAFacetylhydrolase, predominantly present in LDL in healthy subjects, is associated with HDL in a patient with LDL deficiency. J Lipid Mediators. 1991;3:27-38.
23. Shall PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins. Circulation. 2001;104:2376-2383.
24. Asliby DT, Rye K-A, Clay MA, Vadas MA, Gamble JR, Barter PJ. Factors influencing the ability of high-density lipoproteins to inhibit the expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vase Biol. 1998;18:1450-1455.
25. 2 in patients with coronary heart disease versus control subjects. Am J Cardiol. 2005;95:1025-1032.
26. Muhlestein JB, May HT, Jensen JR, Home BD, Lanman RB, Lavasani F, Wolfert RL, Pearson RR, Yannicelli D, Anderson JL. The resduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia. J Am Coll. Cardiol. 2006;48:396-401.
27. Tsimihodimos V, Kostoula A, Kakafika A, Bairaktari E, Tselepis AD, Mikhailidis DP, Elisaf M. Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values. J Cardiovasc Pharmacol Ther. 2004;9:27-33.
28. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, Bloomfield HE, Robins SJ. LDL and HDL particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation. 2006:113: 1556-1563.
29. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996;276:875-881.
30. 2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005:165:2479 2484.